Product Description
Kinoxis' lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms. KNX100 has a novel, undisclosed mechanism of action, and a Phase 1 clinical trial has been completed under a US IND. The company is also exploring other indications for its lead compound, KNX100, as promising preclinical results have been achieved in animal models of alcohol use disorders, methamphetamine, cocaine, and nicotine, as well as models of agitation and aggression. (Sourced from: https://kinoxistherapeutics.com/pipeline/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kinoxis Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dementia
Phase 1: Healthy Volunteers|Opioid-Related Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04901078 |
KTX101 | P1 |
Completed |
Opioid-Related Disorders |
2023-09-30 |
69% |
2025-01-07 |
Patient Enrollment|Primary Endpoints|Treatments |
ACTRN12624000747527 |
CARES-X | P2 |
Recruiting |
Dementia |
2026-10-30 |
2026-01-31 |
Patient Enrollment|Primary Completion Date|Treatments |
|
ACTRN12625000020482 |
ACTRN12625000020482 | P1 |
Completed |
Healthy Volunteers |
2025-06-29 |
2025-09-16 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|